Why ResMed Inc. (RMD) Stock Fell 9.1% on Oct 30, 2026
What happened
ResMed beat Q1 fiscal 2027 earnings (non-GAAP EPS $2.91 vs. $2.67–$2.68 expected; revenue $1.41B) and gross margin improved, per Zacks, yet the stock fell 8.26% to $231.95. The decline stems from management's decision to reiterate rather than raise full-year guidance despite the beat, combined with the permanent discontinuation of its Astral 100 and 150 portable ventilator lines due to a circuit board safety issue—creating an estimated $75M revenue headwind (~130 basis points) for fiscal 2027. Volume is elevated at 2.18x the time-adjusted average, signaling intensified selling pressure.
Management commentary on the ventilator discontinuation's operational and supply-chain impact during the next earnings call or investor update; Q2 fiscal 2027 results (scheduled 2027-01-28) and whether consensus EPS estimate of $3.03 holds against the revised guidance envelope.
Other developments that session
ResMed Inc. (RMD) filed its 10-Q on 2026-10-30.
ResMed beat Q1 FY2027 earnings and revenue estimates while expanding gross margins on strong sleep device demand.
Frequently asked questions
Why did ResMed Inc. (RMD) stock fall on Oct 30, 2026?
ResMed beat Q1 fiscal 2027 earnings (non-GAAP EPS $2.91 vs. $2.67–$2.68 expected; revenue $1.41B) and gross margin improved, per Zacks, yet the stock fell 8.26% to $231.95. The decline stems from management's decision to reiterate rather than raise full-year guidance despite the beat, combined with the permanent discontinuation of its Astral 100 and 150 portable ventilator lines due to a circuit board safety issue—creating an estimated $75M revenue headwind (~130 basis points) for fiscal 2027. Volume is elevated at 2.18x the time-adjusted average, signaling intensified selling pressure.
How much did RMD stock fall on Oct 30, 2026?
RMD fell 9.1% during the Oct 30, 2026 trading session.
